Myeloma generally refers to multiple myeloma. Multiple myeloma does not require treatment when there is no indication for treatment, but is treated when there is an indication, and high-risk asymptomatic individuals can be given intervention through treatment at an early stage. 1. In general, asymptomatic patients with smoldering myeloma do not need to be treated. 2. Treatment should only be initiated for multiple myeloma that meets the therapeutic indications. For high-risk asymptomatic multiple myeloma patients, 80% of patients can be converted to multiple myeloma within 2 years, so intervention can be given at an early stage with treatment. Drugs include bortezomib and lenalidomide. High-risk asymptomatic multiple myeloma is defined as creatinine clearance <40 ml/min, ≥60% abnormal plasma cells in the bone marrow, bone damage greater than 5 cm detected by whole-body low-dose CT, serum free light chain ratio ≥100, magnetic resonance imaging suggestive of more than 1 bone lesion, and positive PET-CT. Because multiple myeloma is a hematologic malignancy originating from plasma cells, the disease can continue to progress without treatment, and serious conditions such as renal failure, secondary infections, thrombosis, hemorrhage, and fractures can occur. If diagnosed with multiple myeloma, early and standardized treatment should be carried out under the guidance of a doctor in order to reduce the adverse effects of the disease.